

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT2755216

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
PFIZER INC.	04/06/2009
RECEIVING PARTY DATA	
Name:	PHIVCO-1 LLC
Street Address:	FIVE MOORE DRIVE
City:	RESEARCHTRIANGLEPARK
State/Country:	NORTH CAROLINA
Postal Code:	27709
PROPERTY NUMBERS Total: 3	
Property Type	Number
Patent Number:	6667314
Patent Number:	7368460
Patent Number:	7576097
CORRESPONDENCE DATA	
Fax Number:	(919)483-7977
Phone:	919483
Email:	usciprtp@gsk.com
<i>Correspondence will be sent via US Mail when the email attempt is unsuccessful.</i>	
Correspondent Name:	GLAXOSMITHKLINE
Address Line 1:	FIVE MOORE DRIVE
Address Line 2:	C2111.2F
Address Line 4:	RESEARCHTRIANGLEPARK, NORTH CAROLINA 27709
ATTORNEY DOCKET NUMBER:	PR65030
NAME OF SUBMITTER:	PATRICIA HARTWELL
Signature:	/Patricia Hartwell/

Date:

03/06/2014

Total Attachments: 10

source=PR65030 PFIZER INC Assigns to PHIVCO-1 LLC#page1.tif
source=PR65030 PFIZER INC Assigns to PHIVCO-1 LLC#page2.tif
source=PR65030 PFIZER INC Assigns to PHIVCO-1 LLC#page3.tif
source=PR65030 PFIZER INC Assigns to PHIVCO-1 LLC#page4.tif
source=PR65030 PFIZER INC Assigns to PHIVCO-1 LLC#page5.tif
source=PR65030 PFIZER INC Assigns to PHIVCO-1 LLC#page6.tif
source=PR65030 PFIZER INC Assigns to PHIVCO-1 LLC#page7.tif
source=PR65030 PFIZER INC Assigns to PHIVCO-1 LLC#page8.tif
source=PR65030 PFIZER INC Assigns to PHIVCO-1 LLC#page9.tif
source=PR65030 PFIZER INC Assigns to PHIVCO-1 LLC#page10.tif

IP ASSIGNMENT

WHEREAS, Pfizer Inc., a Delaware corporation with its registered address at 235 East 42nd Street, New York, NY 10017 (the "Assignor") owns certain rights in (A) the patents and patent applications each listed on Part 1 of Appendix A; (B) the trade marks and trade mark applications each listed on Part 2 of Appendix A; and (C) the domain names each listed on Part 3 of Appendix A (the "Domain Names"); (whether or not any of these is registered) and in each case including applications and rights to apply for registration of any such thing) (each of (A), (B) and (C) the "Intellectual Property Rights"); and

WHEREAS, on April 16, 2009 Pfizer Inc. ("Pfizer"), GlaxoSmithKline plc ("GSK") and GlaxoSmithKline Newco Limited ("Mercury") entered into a Share Purchase Agreement ("the SPA Agreement") in connection with the proposed joint venture between Pfizer and GSK to create a new specialist company dedicated to the research, development and commercialization of HIV medicines (the "Transaction"); and

WHEREAS, to give effect to the Transaction the Assignor wishes to transfer to PHIVCO-1 LLC., a Delaware corporation with registered number 4731421 (the "Assignee"), and the Assignee desires to acquire and assume from the Assignor, such right, title and interest as the Assignor may have in and to the Intellectual Property Rights listed on Appendix A;

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Assignor does hereby sell, transfer, convey and assign to the Assignee such entire right, title and interest as it may have in and to:

- (I) the Intellectual Property Rights listed on attached Appendix A;
- (II) in the case of the patents and patent applications listed on Part 1 of Appendix A, such right title and interest it may have in any patents issuing therefrom, and any continuations, confirmations, divisionals, re-examinations, reissues, revalidations, registrations, supplemental protection certificates or extensions of term, including patent term restoration of any of the foregoing patents and applications and all foreign counterparts thereof and including such right, title and interest as it may have in the

inventions covered by the claims of such patents and patent applications (collectively, the "Assigned Patents");

- (III) in the case of the trade marks and trade mark applications listed in Part 2 of Appendix 1, such right title and interest it may have in the goodwill of the business connected with the use of the trade marks and applications and symbolized thereby; and
- (IV) such right title and interest as it may have to sue and recover for any future infringement, damage or injury to any of the Intellectual Property Rights, and for any past infringement, damage or injury to any of the Intellectual Property Rights by any third parties, and collect profits or damages with respect to the same,

the same to be held and enjoyed by Assignee, for its own use and behalf and the use and behalf of its successors and assigns, to the full end of the term or terms for which such Intellectual Property Rights may be granted as fully and entirely as the same would have been held and enjoyed by the Assignor had this sale and assignment not been made.

The Assignor listed as the registered holder of (A) such patent or patent applications; (B) such trade mark and trade mark applications; and (C) such domain names hereby authorizes and requests the Commissioner or Director of Patents and Trademarks of the United States; the relevant register at which the Domain Names are registered; and any official of any country foreign to the United States whose duty it is to issue patents, trade marks or domain names, to issue and transfer the relevant Intellectual Property Rights to Assignee, its successors and assigns, in accordance with the terms of the assignment, or otherwise as Assignee may direct.


This Assignment is binding on the Assignor, its successors and assigns, and will inure to the benefit of Assignee, its successors and assigns. Nothing in this instrument, express or implied, is intended or shall be construed to confer upon, or give to, any person, corporation or entity other than Assignee, its successors and assigns, any remedy or claim under or by reason of this instrument, or any terms, covenants or conditions hereof, and all the terms, covenants and conditions in this instrument shall be for the sole and exclusive benefit of Assignee and its successors and assigns.

The Assignee acknowledges that the Assignor gives no representation, warranty, indemnity or guarantee in respect of any of the Intellectual Property Rights listed on Appendix A


or ancillary rights assigned hereunder and the Assignor's rights in and to the Intellectual Property Rights are assigned on an 'as is' basis. This is without prejudice to the provisions of any other agreement implementing the Transaction.

IN WITNESS WHEREOF, the Assignor and Assignee have caused this Assignment to be executed as of the date written below.

Pfizer Inc.

By: 
Name: KATHERINE YANG
Title: ATTORNEY-IN-FACT
Date:
Date:

PHIVCO-1 LLC

By: 
Name: ANDREW MONTUORI
Title: ATTORNEY-IN-FACT
Date:
Date:

PC 10925²

Patent Number	Application Number	Title	Proprietor	Country
AP1965	AP/P/2002/002663	CCR5 Receptor Antagonists	Pfizer Inc.	A.R.I.P.O.
1526134	4004193.1	CCR5 Receptor Antagonists	Pfizer Inc.	Albania
1284974	AL/P/04/01060	CCR5 Receptor Antagonists	Pfizer Inc.	Albania
	AL-E-5081	CCR5 Receptor Antagonists	Pfizer Inc.	Albania
3464	20246	CCR5 Receptor Antagonists	Pfizer Inc.	Algeria
Nov-05	Nov-05	CCR5 Receptor Antagonists	Pfizer Inc.	Antigua
	P070101273	CCR5 Receptor Antagonists	Pfizer Inc.	Argentina
AR028622B1	P010102486	CCR5 Receptor Antagonists	Pfizer Inc.	Argentina
7580	200401056	CCR5 Receptor Antagonists	Pfizer Inc.	Armenia
5382	200201141	CCR5 Receptor Antagonists	Pfizer Inc.	Armenia
2001252482	2001252482	CCR5 Receptor Antagonists	Pfizer Inc.	Australia
2001252482	2001252482	CCR5 Receptor Antagonists	Pfizer Inc.	Australia
E407134	4004193.1	CCR5 Receptor Antagonists	Pfizer Inc.	Austria
SZ 6/2008	SZ 6/2008	CCR5 Receptor Antagonists	Pfizer Inc.	Austria
E260914	1925808.6	CCR5 Receptor Antagonists	Pfizer Inc.	Austria
7580	200401056	CCR5 Receptor Antagonists	Pfizer Inc.	Azerbaijan
5382	200201141	CCR5 Receptor Antagonists	Pfizer Inc.	Azerbaijan
1378	1378	CCR5 Receptor Antagonists	Pfizer Inc.	Bahamas
GC0000615	1387	CCR5 Receptor Antagonists	Pfizer Inc.	Bahrain
1003712	131/2001	CCR5 Receptor Antagonists	Pfizer Inc.	Bangladesh
	2001/895	CCR5 Receptor Antagonists	Pfizer Inc.	Barbados
5382	200201141	CCR5 Receptor Antagonists	Pfizer Inc.	Belarus
7580	200401056	CCR5 Receptor Antagonists	Pfizer Inc.	Belarus
1526134	4004193.1	CCR5 Receptor Antagonists	Pfizer Inc.	Belgium
2008C/009	2008C/009	CCR5 Receptor Antagonists	Pfizer Inc.	Belgium
1284974	1925808.6	CCR5 Receptor Antagonists	Pfizer Inc.	Belgium
12264	1200200343	CCR5 Receptor Antagonists	Pfizer Inc.	Benin
271EP	271	CCR5 Receptor Antagonists	Pfizer Inc.	Bermuda
	SP087-2001	CCR5 Receptor Antagonists	Pfizer Inc.	Bolivia
	BAP021253A	CCR5 Receptor Antagonists	Pfizer Inc.	Bosnia-Herzegovina

² Pfizer Limited, C.P. Pharmaceuticals International C.V. and Pfizer Inc. each has a beneficial interest in the patents and patent applications listed under PC 10925. The Pfizer Limited and C.P. Pharmaceuticals International C.V. beneficial rights are not assigned under this agreement.

Patent Number	Application Number	Title	Proprietor	Country
	PI0110955-3	CCR5 Receptor Antagonists	Pfizer Inc.	Brazil
	107140	CCR5 Receptor Antagonists	Pfizer Inc.	Bulgaria
12264	1200200343	CCR5 Receptor Antagonists	Pfizer Inc.	Burkina Faso
12264	1200200343	CCR5 Receptor Antagonists	Pfizer Inc.	Cameroon
		CCR5 Receptor Antagonists	Pfizer Inc.	Canada
2408909	2408909	CCR5 Receptor Antagonists	Pfizer Inc.	Canada
1284974	1284974	CCR5 Receptor Antagonists	Pfizer Inc.	Cayman Islands
12264	1200200343	CCR5 Receptor Antagonists	Pfizer Inc.	Central African Republic
12264	1200200343	CCR5 Receptor Antagonists	Pfizer Inc.	Chad
	1177-01	CCR5 Receptor Antagonists	Pfizer Inc.	Chile
	2 0061E+11	CCR5 Receptor Antagonists	Pfizer Inc.	China P.R.
ZL01808828.7	1808828.7	CCR5 Receptor Antagonists	Pfizer Inc.	China P.R.
ZL200510006815	2 0061E+11	CCR5 Receptor Antagonists	Pfizer Inc.	China P.R.
	2101292	CCR5 Receptor Antagonists	Pfizer Inc.	Colombia
12264	1200200343	CCR5 Receptor Antagonists	Pfizer Inc.	Congo
	10145	CCR5 Receptor Antagonists	Pfizer Inc.	Costa Rica
	6600	CCR5 Receptor Antagonists	Pfizer Inc.	Costa Rica
	P20020938A	CCR5 Receptor Antagonists	Pfizer Inc.	Croatia
	2002-0243	CCR5 Receptor Antagonists	Pfizer Inc.	Cuba
CY20081101203	4004193.1	CCR5 Receptor Antagonists	Pfizer Inc.	Cyprus
CY2008/2006	CY2008/00006	CCR5 Receptor Antagonists	Pfizer Inc.	Cyprus
CY1101925	1925808.6	CCR5 Receptor Antagonists	Pfizer Inc.	Cyprus
299102	PV2002-3806	CCR5 Receptor Antagonists	Pfizer Inc.	Czech Republic
29910/134	SPC/CZ2008/134	CCR5 Receptor Antagonists	Pfizer Inc.	Czech Republic
1526134	4004193.1	CCR5 Receptor Antagonists	Pfizer Inc.	Denmark
CA2008 00018	CA2008 00018	CCR5 Receptor Antagonists	Pfizer Inc.	Denmark
1284974	1925808.6	CCR5 Receptor Antagonists	Pfizer Inc.	Denmark
	SP-01-4089	CCR5 Receptor Antagonists	Pfizer Inc.	Ecuador
24137	535/2001	CCR5 Receptor Antagonists	Pfizer Inc.	Egypt
EE05110	0656/02PC	CCR5 Receptor Antagonists	Pfizer Inc.	Estonia
	C20090002	CCR5 Receptor Antagonists	Pfizer Inc.	Estonia
7580	200401056	CCR5 Receptor Antagonists	Pfizer Inc.	Eurasian Patent Convention
5382	200201141	CCR5 Receptor Antagonists	Pfizer Inc.	Eurasian Patent Convention
EP1284974	1925808.6	CCR5 Receptor Antagonists	Pfizer Inc.	European Patent Convention
	8163025.3	CCR5 Receptor Antagonists	Pfizer Inc.	European Patent Convention

Patent Number	Application Number	Title	Proprietor	Country
1526134	4004193.1	CCR5 Receptor Antagonists	Pfizer Inc.	European Patent Convention
1284974	1925808.6	CCR5 Receptor Antagonists	Pfizer Inc.	Finland
1526134	4004193.1	CCR5 Receptor Antagonists	Pfizer Inc.	Finland
	C20080006	CCR5 Receptor Antagonists	Pfizer Inc.	Finland
1526134	4004193.1	CCR5 Receptor Antagonists	Pfizer Inc.	France
08C0007	08C0007	CCR5 Receptor Antagonists	Pfizer Inc.	France
1284974	1925808.6	CCR5 Receptor Antagonists	Pfizer Inc.	France
12264	1200200343	CCR5 Receptor Antagonists	Pfizer Inc.	Gabon
AP1965	AP/P/2002/002663	CCR5 Receptor Antagonists	Pfizer Inc.	Gambia
P3799	AP 2001 004960	CCR5 Receptor Antagonists	Pfizer Inc.	Georgia
60102233.5-08	1925808.6	CCR5 Receptor Antagonists	Pfizer Inc.	Germany
60135685.3-08	4004193.1	CCR5 Receptor Antagonists	Pfizer Inc.	Germany
	12 2008000011.4	CCR5 Receptor Antagonists	Pfizer Inc.	Germany
AP1965	AP/P/2002/002663	CCR5 Receptor Antagonists	Pfizer Inc.	Ghana
1526134	4004193.1	CCR5 Receptor Antagonists	Pfizer Inc.	Great Britain
	SPC/GB08/014	CCR5 Receptor Antagonists	Pfizer Inc.	Great Britain
3048216	1925808.6	CCR5 Receptor Antagonists	Pfizer Inc.	Greece
3066807	4004193.1	CCR5 Receptor Antagonists	Pfizer Inc.	Greece
8000276	20080800008	CCR5 Receptor Antagonists	Pfizer Inc.	Greece
15/2005	1284974	CCR5 Receptor Antagonists	Pfizer Inc.	Grenada
4903/198/18	PI-2001-0096	CCR5 Receptor Antagonists	Pfizer Inc.	Guatemala
12264	1200200343	CCR5 Receptor Antagonists	Pfizer Inc.	Guinea
12264	1200200343	CCR5 Receptor Antagonists	Pfizer Inc.	Guinea-Bissau
GC0000615	GCC/P/2001/1387	CCR5 Receptor Antagonists	Pfizer Inc.	Gulf Cooperation Council
1460	1460	CCR5 Receptor Antagonists	Pfizer Inc.	Guyana
4.33	PI/US2001/102	CCR5 Receptor Antagonists	Pfizer Inc.	Honduras
	6111446.1	CCR5 Receptor Antagonists	Pfizer Inc.	Hong Kong
HK1054927	3107045.7	CCR5 Receptor Antagonists	Pfizer Inc.	Hong Kong
HK1078573	5110416	CCR5 Receptor Antagonists	Pfizer Inc.	Hong Kong
225810	P0302474	CCR5 Receptor Antagonists	Pfizer Inc.	Hungary
	S0800003	CCR5 Receptor Antagonists	Pfizer Inc.	Hungary
	P0700311	CCR5 Receptor Antagonists	Pfizer Inc.	Hungary
2511	6566	CCR5 Receptor Antagonists	Pfizer Inc.	Iceland
	0005/09	CCR5 Receptor Antagonists	Pfizer Inc.	Iceland
	1577/DELNP/2006	CCR5 Receptor Antagonists	Pfizer Inc.	India

Patent Number	Application Number	Title	Promotor	Country
211212	IN/PCT/2002/00923/DE	CCR5 Receptor Antagonists	Pfizer Inc.	India
224374	5511/DELNP/2005	CCR5 Receptor Antagonists	Pfizer Inc.	India
ID0011260	WOO 2002 002671	CCR5 Receptor Antagonists	Pfizer Inc.	Indonesia
1284974	1925808.6	CCR5 Receptor Antagonists	Pfizer Inc.	Ireland
1526134	4004193.1	CCR5 Receptor Antagonists	Pfizer Inc.	Ireland
2008/008	2008/008	CCR5 Receptor Antagonists	Pfizer Inc.	Ireland
	152531	CCR5 Receptor Antagonists	Pfizer Inc.	Israel
1284974	1925808.6	CCR5 Receptor Antagonists	Pfizer Inc.	Italy
1526134	4004193.1	CCR5 Receptor Antagonists	Pfizer Inc.	Italy
1039	1039	CCR5 Receptor Antagonists	Pfizer Inc.	Italy
12264	1200200343	CCR5 Receptor Antagonists	Pfizer Inc.	Ivory Coast
3722	18/1/4516	CCR5 Receptor Antagonists	Pfizer Inc.	Jamaica
3693957	2001-566293	CCR5 Receptor Antagonists	Pfizer Inc.	Japan
	2005-38062	CCR5 Receptor Antagonists	Pfizer Inc.	Japan
	Awaiting	CCR5 Receptor Antagonists	Pfizer Inc.	Japan
5382	200201141	CCR5 Receptor Antagonists	Pfizer Inc.	Kazakhstan
7580	200401056	CCR5 Receptor Antagonists	Pfizer Inc.	Kazakhstan
AP1965	AP/P/2002/002663	CCR5 Receptor Antagonists	Pfizer Inc.	Kenya
523501	10-2002-7015934	CCR5 Receptor Antagonists	Pfizer Inc.	Korea South
548854	10-2005-7003492	CCR5 Receptor Antagonists	Pfizer Inc.	Korea South
548854	2008-0038187	CCR5 Receptor Antagonists	Pfizer Inc.	Korea South
523501	2008-0038191	CCR5 Receptor Antagonists	Pfizer Inc.	Korea South
		CCR5 Receptor Antagonists	Pfizer Inc.	Kosovo
GC0000615	1387	CCR5 Receptor Antagonists	Pfizer Inc.	Kuwait
5382	200201141	CCR5 Receptor Antagonists	Pfizer Inc.	Kyrgyzstan
7580	200401056	CCR5 Receptor Antagonists	Pfizer Inc.	Kyrgyzstan
1284974	1925808.6	CCR5 Receptor Antagonists	Pfizer Inc.	Latvia
1526134	4004193.1	CCR5 Receptor Antagonists	Pfizer Inc.	Latvia
C/LV2008/0003	C/LV2008/0003	CCR5 Receptor Antagonists	Pfizer Inc.	Latvia
AP1965	AP/P/2002/002663	CCR5 Receptor Antagonists	Pfizer Inc.	Lesotho
1284974	1925808.6	CCR5 Receptor Antagonists	Pfizer Inc.	Lithuania
1526134	4004193.1	CCR5 Receptor Antagonists	Pfizer Inc.	Lithuania
C 1284974	PA 2008 004	CCR5 Receptor Antagonists	Pfizer Inc.	Lithuania
1526134	4004193.1	CCR5 Receptor Antagonists	Pfizer Inc.	Luxembourg
91417	91 417	CCR5 Receptor Antagonists	Pfizer Inc.	Luxembourg

Patent Number	Application Number	Title	Proprietor	Country
1284974	1925808.6	CCR5 Receptor Antagonists	Pfizer Inc.	Luxembourg
J/000189	J000189	CCR5 Receptor Antagonists	Pfizer Inc.	Macao
J/000081	J/000081	CCR5 Receptor Antagonists	Pfizer Inc.	Macao
1284974	1925808.6	CCR5 Receptor Antagonists	Pfizer Inc.	Macedonia
1526134	4004193.1	CCR5 Receptor Antagonists	Pfizer Inc.	Macedonia
AP1965	AP/P/2002/002663	CCR5 Receptor Antagonists	Pfizer Inc.	Malawi
MY-131019-A	PI20012461	CCR5 Receptor Antagonists	Pfizer Inc.	Malaysia
	PI20041980	CCR5 Receptor Antagonists	Pfizer Inc.	Malaysia
	Awaiting	CCR5 Receptor Antagonists	Pfizer Inc.	Malaysia
12264	1200200343	CCR5 Receptor Antagonists	Pfizer Inc.	Mali
1578	1578	CCR5 Receptor Antagonists	Pfizer Inc.	Malta
SPC/8/2008	SPC/8/2008	CCR5 Receptor Antagonists	Pfizer Inc.	Malta
12264	1200200343	CCR5 Receptor Antagonists	Pfizer Inc.	Mauritania
231272	PA/A2002/011631	CCR5 Receptor Antagonists	Pfizer Inc.	Mexico
5332	200201141	CCR5 Receptor Antagonists	Pfizer Inc.	Moldova
7580	200401056	CCR5 Receptor Antagonists	Pfizer Inc.	Moldova
1284974	1925808.6	CCR5 Receptor Antagonists	Pfizer Inc.	Monaco
2206	3002	CCR5 Receptor Antagonists	Pfizer Inc.	Mongolia
	P-693/08	CCR5 Receptor Antagonists	Pfizer Inc.	Montenegro
26902	26910	CCR5 Receptor Antagonists	Pfizer Inc.	Morocco
AP1965	AP/P/2002/002663	CCR5 Receptor Antagonists	Pfizer Inc.	Mozambique
1526134	4004193.1	CCR5 Receptor Antagonists	Pfizer Inc.	Netherlands
300338	300338	CCR5 Receptor Antagonists	Pfizer Inc.	Netherlands
1284974	1925808.6	CCR5 Receptor Antagonists	Pfizer Inc.	Netherlands
521477	521477	CCR5 Receptor Antagonists	Pfizer Inc.	New Zealand
1569 RPI	2001-0050	CCR5 Receptor Antagonists	Pfizer Inc.	Nicaragua
12264	1200200343	CCR5 Receptor Antagonists	Pfizer Inc.	Niger
RP.14926	202/2001	CCR5 Receptor Antagonists	Pfizer Inc.	Nigeria
	20025227	CCR5 Receptor Antagonists	Pfizer Inc.	Norway
12264	1200200343	CCR5 Receptor Antagonists	Pfizer Inc.	O.A.P.I.
GC0000615	1387	CCR5 Receptor Antagonists	Pfizer Inc.	Oman
139892	490/2001	CCR5 Receptor Antagonists	Pfizer Inc.	Pakistan
139897	176/2007	CCR5 Receptor Antagonists	Pfizer Inc.	Pakistan
139896	175/2007	CCR5 Receptor Antagonists	Pfizer Inc.	Pakistan
85171	PI/PA01/85171	CCR5 Receptor Antagonists	Pfizer Inc.	Panama

Patent Number	Application Number	Title	Proprietor	Country
	11329/2001	CCR5 Receptor Antagonists	Pfizer Inc.	Paraguay
3317	476.2001	CCR5 Receptor Antagonists	Pfizer Inc.	Peru
1-2001-01313	1-2001-01313	CCR5 Receptor Antagonists	Pfizer Inc.	Philippines
		CCR5 Receptor Antagonists	Pfizer Inc.	Philippines
200651	P358267	CCR5 Receptor Antagonists	Pfizer Inc.	Poland
	122/200551	CCR5 Receptor Antagonists	Pfizer Inc.	Poland
1284974	1925808.6	CCR5 Receptor Antagonists	Pfizer Inc.	Portugal
1526134	4004193.1	CCR5 Receptor Antagonists	Pfizer Inc.	Portugal
321	321	CCR5 Receptor Antagonists	Pfizer Inc.	Portugal
GC0000615	1387	CCR5 Receptor Antagonists	Pfizer Inc.	Qatar
1526134	4004193.1	CCR5 Receptor Antagonists	Pfizer Inc.	Romania
	C2008 005	CCR5 Receptor Antagonists	Pfizer Inc.	Romania
1284974	1925808.6	CCR5 Receptor Antagonists	Pfizer Inc.	Romania
5382	200201141	CCR5 Receptor Antagonists	Pfizer Inc.	Russian Federation
7580	200401056	CCR5 Receptor Antagonists	Pfizer Inc.	Russian Federation
GC0000615	1387	CCR5 Receptor Antagonists	Pfizer Inc.	Saudi Arabia
12264	1200200343	CCR5 Receptor Antagonists	Pfizer Inc.	Senegal
	P-822/02	CCR5 Receptor Antagonists	Pfizer Inc.	Serbia
AP1965	AP/P/2002/002663	CCR5 Receptor Antagonists	Pfizer Inc.	Sierra Leone
92972	200206765-0	CCR5 Receptor Antagonists	Pfizer Inc.	Singapore
286129	PV1643-2002S	CCR5 Receptor Antagonists	Pfizer Inc.	Slovak Republic
DO 72	PDO 5003-2008	CCR5 Receptor Antagonists	Pfizer Inc.	Slovak Republic
1284974	1925808.6	CCR5 Receptor Antagonists	Pfizer Inc.	Slovenia
1526134	4004193.1	CCR5 Receptor Antagonists	Pfizer Inc.	Slovenia
200840005	200840005	CCR5 Receptor Antagonists	Pfizer Inc.	Slovenia
2002/9516	2002/9516	CCR5 Receptor Antagonists	Pfizer Inc.	South Africa
2311126	4004193.1	CCR5 Receptor Antagonists	Pfizer Inc.	Spain
	200800013	CCR5 Receptor Antagonists	Pfizer Inc.	Spain
1284974	1925808.6	CCR5 Receptor Antagonists	Pfizer Inc.	Spain
12927	12927	CCR5 Receptor Antagonists	Pfizer Inc.	Sri Lanka
PT021/2005	PT021/2005	CCR5 Receptor Antagonists	Pfizer Inc.	St. Lucia
AP1965	AP/P/2002/002663	CCR5 Receptor Antagonists	Pfizer Inc.	Sudan
AP1965	AP/P/2002/002663	CCR5 Receptor Antagonists	Pfizer Inc.	Swaziland
1284974	1925808.6	CCR5 Receptor Antagonists	Pfizer Inc.	Sweden
1526134	4004193.1	CCR5 Receptor Antagonists	Pfizer Inc.	Sweden

Patent Number	Application Number	Title	Proprietor	Country
0890011-012/12	0890011-0	CCR5 Receptor Antagonists	Pfizer Inc.	Sweden
1526134	4004193.1	CCR5 Receptor Antagonists	Pfizer Inc.	Switzerland
	C01264974/01	CCR5 Receptor Antagonists	Pfizer Inc.	Switzerland
1264974	1925808.6	CCR5 Receptor Antagonists	Pfizer Inc.	Switzerland
1230160	90112055	CCR5 Receptor Antagonists	Pfizer Inc.	Taiwan
	90112055	CCR5 Receptor Antagonists	Pfizer Inc.	Taiwan
5382	200201141	CCR5 Receptor Antagonists	Pfizer Inc.	Tajikistan
7580	200401056	CCR5 Receptor Antagonists	Pfizer Inc.	Tajikistan
	65701	CCR5 Receptor Antagonists	Pfizer Inc.	Thailand
12264	1200200343	CCR5 Receptor Antagonists	Pfizer Inc.	Togo
	TT/A/2005/00081	CCR5 Receptor Antagonists	Pfizer Inc.	Trinidad & Tobago
TT/P/2005/0044	TT/A/2002/00156	CCR5 Receptor Antagonists	Pfizer Inc.	Trinidad & Tobago
18471	SN.01077	CCR5 Receptor Antagonists	Pfizer Inc.	Tunisia
TR200808263T4	4004193.1	CCR5 Receptor Antagonists	Pfizer Inc.	Turkey
TR200400541T4	1925808.6	CCR5 Receptor Antagonists	Pfizer Inc.	Turkey
5382	200201141	CCR5 Receptor Antagonists	Pfizer Inc.	Turkmenistan
7580	200401056	CCR5 Receptor Antagonists	Pfizer Inc.	Turkmenistan
AP1965	AP/P/2002/002663	CCR5 Receptor Antagonists	Pfizer Inc.	Uganda
73170	2002119374	CCR5 Receptor Antagonists	Pfizer Inc.	Ukraine
GC0000615	1387	CCR5 Receptor Antagonists	Pfizer Inc.	United Arab Emirates
	09/865950	CCR5 Receptor Antagonists	Pfizer Inc.	United States
6667314	09/865950	CCR5 Receptor Antagonists	Pfizer Inc.	United States
7368460	10/678836	CCR5 Receptor Antagonists	Pfizer Inc.	United States
7576097	12/023334	CCR5 Receptor Antagonists	Pfizer Inc.	United States
	26.727	CCR5 Receptor Antagonists	Pfizer Inc.	Uruguay
IAP03117	IAP20020776	CCR5 Receptor Antagonists	Pfizer Inc.	Uzbekistan
	1126-01	CCR5 Receptor Antagonists	Pfizer Inc.	Venezuela
	1-2002-01067	CCR5 Receptor Antagonists	Pfizer Inc.	Vietnam
AP1965	AP/P/2002/002663	CCR5 Receptor Antagonists	Pfizer Inc.	Zimbabwe

PATENT

RECORDED: 03/06/2014

REEL: 032361 FRAME: 0540